Drug metabolism alterations in nonalcoholic fatty liver disease

Matthew D. Merrell, Nathan J Cherrington

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Drug-metabolizing enzymes play a vital role in the elimination of the majority of therapeutic drugs. The major organ involved in drug metabolism is the liver. Chronic liver diseases have been identified as a potential source of significant interindividual variation in metabolism. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, affecting between 60 and 90 million Americans, yet the vast majority of NAFLD patients are undiagnosed. NAFLD encompasses a spectrum of pathologies, ranging from steatosis to nonalcoholic steatohepatitis and fibrosis. Numerous animal studies have investigated the effects of NAFLD on hepatic gene expression, observing significant alterations in mRNA, protein, and activity levels. Information on the effects of NAFLD in human patients is limited, though several significant investigations have recently been published. Significant alterations in the activity of drug-metabolizing enzymes may affect the clearance of therapeutic drugs, with the potential to result in adverse drug reactions. With the enormous prevalence of NAFLD, it is conceivable that every drug currently on the market is being given to patients with NAFLD. The current review is intended to present the results from both animal models and human patients, summarizing the observed alterations in the expression and activity of the phase I and II drug-metabolizing enzymes.

Original languageEnglish (US)
Pages (from-to)317-334
Number of pages18
JournalDrug Metabolism Reviews
Volume43
Issue number3
DOIs
StatePublished - Aug 2011

Fingerprint

Pharmaceutical Preparations
Liver Diseases
Chronic Disease
Enzymes
Non-alcoholic Fatty Liver Disease
Liver
Drug-Related Side Effects and Adverse Reactions
Fibrosis
Animal Models
Pathology
Gene Expression
Messenger RNA
Therapeutics
Proteins

Keywords

  • Cytochrome p450
  • Glutathione S-transferase
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Drug metabolism alterations in nonalcoholic fatty liver disease. / Merrell, Matthew D.; Cherrington, Nathan J.

In: Drug Metabolism Reviews, Vol. 43, No. 3, 08.2011, p. 317-334.

Research output: Contribution to journalArticle

@article{cd3e39dc15ab45cfacd80a6949c8f526,
title = "Drug metabolism alterations in nonalcoholic fatty liver disease",
abstract = "Drug-metabolizing enzymes play a vital role in the elimination of the majority of therapeutic drugs. The major organ involved in drug metabolism is the liver. Chronic liver diseases have been identified as a potential source of significant interindividual variation in metabolism. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, affecting between 60 and 90 million Americans, yet the vast majority of NAFLD patients are undiagnosed. NAFLD encompasses a spectrum of pathologies, ranging from steatosis to nonalcoholic steatohepatitis and fibrosis. Numerous animal studies have investigated the effects of NAFLD on hepatic gene expression, observing significant alterations in mRNA, protein, and activity levels. Information on the effects of NAFLD in human patients is limited, though several significant investigations have recently been published. Significant alterations in the activity of drug-metabolizing enzymes may affect the clearance of therapeutic drugs, with the potential to result in adverse drug reactions. With the enormous prevalence of NAFLD, it is conceivable that every drug currently on the market is being given to patients with NAFLD. The current review is intended to present the results from both animal models and human patients, summarizing the observed alterations in the expression and activity of the phase I and II drug-metabolizing enzymes.",
keywords = "Cytochrome p450, Glutathione S-transferase, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis",
author = "Merrell, {Matthew D.} and Cherrington, {Nathan J}",
year = "2011",
month = "8",
doi = "10.3109/03602532.2011.577781",
language = "English (US)",
volume = "43",
pages = "317--334",
journal = "Drug Metabolism Reviews",
issn = "0360-2532",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Drug metabolism alterations in nonalcoholic fatty liver disease

AU - Merrell, Matthew D.

AU - Cherrington, Nathan J

PY - 2011/8

Y1 - 2011/8

N2 - Drug-metabolizing enzymes play a vital role in the elimination of the majority of therapeutic drugs. The major organ involved in drug metabolism is the liver. Chronic liver diseases have been identified as a potential source of significant interindividual variation in metabolism. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, affecting between 60 and 90 million Americans, yet the vast majority of NAFLD patients are undiagnosed. NAFLD encompasses a spectrum of pathologies, ranging from steatosis to nonalcoholic steatohepatitis and fibrosis. Numerous animal studies have investigated the effects of NAFLD on hepatic gene expression, observing significant alterations in mRNA, protein, and activity levels. Information on the effects of NAFLD in human patients is limited, though several significant investigations have recently been published. Significant alterations in the activity of drug-metabolizing enzymes may affect the clearance of therapeutic drugs, with the potential to result in adverse drug reactions. With the enormous prevalence of NAFLD, it is conceivable that every drug currently on the market is being given to patients with NAFLD. The current review is intended to present the results from both animal models and human patients, summarizing the observed alterations in the expression and activity of the phase I and II drug-metabolizing enzymes.

AB - Drug-metabolizing enzymes play a vital role in the elimination of the majority of therapeutic drugs. The major organ involved in drug metabolism is the liver. Chronic liver diseases have been identified as a potential source of significant interindividual variation in metabolism. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, affecting between 60 and 90 million Americans, yet the vast majority of NAFLD patients are undiagnosed. NAFLD encompasses a spectrum of pathologies, ranging from steatosis to nonalcoholic steatohepatitis and fibrosis. Numerous animal studies have investigated the effects of NAFLD on hepatic gene expression, observing significant alterations in mRNA, protein, and activity levels. Information on the effects of NAFLD in human patients is limited, though several significant investigations have recently been published. Significant alterations in the activity of drug-metabolizing enzymes may affect the clearance of therapeutic drugs, with the potential to result in adverse drug reactions. With the enormous prevalence of NAFLD, it is conceivable that every drug currently on the market is being given to patients with NAFLD. The current review is intended to present the results from both animal models and human patients, summarizing the observed alterations in the expression and activity of the phase I and II drug-metabolizing enzymes.

KW - Cytochrome p450

KW - Glutathione S-transferase

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=79960745166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960745166&partnerID=8YFLogxK

U2 - 10.3109/03602532.2011.577781

DO - 10.3109/03602532.2011.577781

M3 - Article

VL - 43

SP - 317

EP - 334

JO - Drug Metabolism Reviews

JF - Drug Metabolism Reviews

SN - 0360-2532

IS - 3

ER -